Trulive secures hundreds of millions in Series C funding to boost cardiovascular platform

Trulive, a rare platform-based interventional innovation company in China focused on "blood flow management," recently officially announced the successful completion of a Series C financing round valued at several hundred million.

Trulive has consistently secured a financing round each year, demonstrating sustained strong confidence from the capital market. This round of financing was jointly completed by multiple institutions, including Oriental Fortune Capital, Guoyuan Equity, Xiamen Venture Capital, Xiajin Innovation, Bozheng Capital, Siming Science and Technology Innovation, along with existing shareholder Tree of Life Capital.

This financing round marks one of several major capital moves completed by Trulive within just a few years. It not only signifies deep market recognition of Trulive's platform-based strategy and commercial prospects, but also reflects a new paradigm where Chinese high-end medical device companies are achieving technological breakthroughs and building ecosystems in the field of cardiovascular intervention.

Since its founding in 2019, Trulive has consistently focused on cardiovascular diseases with high fatality and disability rates – areas where the Chinese market remains largely untapped. Guided by its mission, the company has rapidly emerged as a significant new force in China's high-end medical device sector.

Particularly in structural heart disease – specifically the mitral and tricuspid valve segments where clinical demand is urgent and the competitive landscape remains fluid – Trulive has established differentiated advantages. The company has innovatively proposed a "1+1>2" synergistic development strategy. By simultaneously developing mitral and tricuspid valve product pipelines and covering both repair and replacement technical pathways, Trulive has established comprehensive, all-scenario solution capabilities and a leading toolbox product system – a rare achievement in China. This addresses diverse treatment needs for patients with different conditions and anatomical structures, effectively filling the gap in China's high-end medical device market for interventional therapies targeting mitral and tricuspid valves.